<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134437">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847079</url>
  </required_header>
  <id_info>
    <org_study_id>NL 38603.078.11</org_study_id>
    <nct_id>NCT01847079</nct_id>
  </id_info>
  <brief_title>Procalcitonin to Guide Obtaining Bloodcultures in the ICU Intensive Care Infection Score</brief_title>
  <acronym>ProBIC/ICIS</acronym>
  <official_title>Procalcitonin to Guide Obtaining Bloodcultures in the ICU. Intensive Care Infection Score.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROBIC

      Rationale: Procalcitonin measurements can reduce the number of blood cultures in the ICU.

      Objective: The investigators suggest that PCT is a marker for blood stream infection in all
      patients in the ICU in whom attending physicians/ intensivists order blood culturing in the
      suspicion of microbial infection. The investigators want to demonstrate that its use for
      guiding blood culturing is cost-effective and safe compared with blood cultures alone.

      Study design: Prospective, non- inferiority, multicenter, single-blinded, cluster-
      randomised cross-over clinical trial.

      Intervention (if applicable): The intensive care units will be allocated into two groups: a
      control group (blood culture) and the intervention group (procalcitonin).

      Main study parameters/endpoints: Safety, expressed as mortality at day 28 and 90, with a
      mortality difference not exceeding a between groups difference of 10% by non-inferiority
      analysis.

      Cost-effectiveness, expressed in euro, calculated by deducting costs of procalcitonin
      testing from saved blood cultures compared with standard treatment spending on blood
      cultures in the control group.

      ICIS

      Rationale: The aim was to evaluate the Intensive Care Infection Score (ICIS) in predicting
      microbial infection and its sequelae in critically ill patients in whom attending
      physicians/ intensivists order blood culturing in the suspicion of microbial infection.

      Objective: Because of the complexity of the pathophysiology of systemic inflammation it is
      unlikely that a single parameter will have sufficient diagnostic accuracy for infection.
      Therefore we will study combining parameters producing a diagnostic score.

      Study design: Prospective, multicenter, cohort trial. Supplement for the control arm of the
      ProBIC study.

      Intervention (if applicable): Blood is drawn for daily routine laboratory measurements and
      collected in K3EDTA aliqnots. The ICIS score is composed of five blood-cell derived
      parameters which can be extracted using the same aliqnots.

      Main study parameters/endpoints: To develop and evaluate a blood- cell derived score to
      enable the diagnosis of microbial infection, its likelihood, its invasiveness and severity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>1. Safety, expressed as mortality at day 28 and 90, with a mortality difference not exceeding a between groups difference of 10% by non-inferiority analysis.</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1130</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Intervention group, procalcitonin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>procalcitonin to guid obtaining bloodcultures in the ICU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group, ICIS, procalcitonin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Measurement of PCT and ICIS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procalcitonin</intervention_name>
    <description>Procalcitonin to guide obtaining bloodcultures</description>
    <arm_group_label>Intervention group, procalcitonin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will need to be over the age of 18 and suffering from an assumed infection
             deemed clinically worthy for blood culturing.

        Exclusion Criteria:

          -  Uncontrolled malignancy

          -  Immunosuppressive or immunostimulatory therapy

          -  Neutropenia, defined as leukocyte count less then 0.5x109/L

          -  Moribund patients

          -  Predetermined illness with an expected death within 24 hours
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick van der Geest, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P.J. van der Geest, MD</last_name>
      <phone>0031622998576</phone>
      <email>p.vandergeest@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>P.J. van der Geest, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ABJ Groeneveld, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3079DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick van der Geest, MD</last_name>
      <phone>0031622998576</phone>
      <email>p.vandergeest@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>PJ van der Geest, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>S Duran, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>P.J. van der Geest</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
